Erik S Mittra

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. ncbi request reprint Comparative morphometrics of the primate apical tuft
    Erik S Mittra
    Division of Nuclear Medicine, Stanford University, Stanford, CA 94305, USA
    Am J Phys Anthropol 134:449-59. 2007
  2. ncbi request reprint A case of three synchronous primary tumors demonstrated by F-18 FDG PET
    Erik Mittra
    Nuclear Medicine Service, VA Palo Alto Health Care System, Palo Alto, California, USA
    Clin Nucl Med 32:666-7. 2007
  3. ncbi request reprint Concurrent metabolic and osseous metastatic disease on a Tc99m-MDP bone scan
    Erik Mittra
    Department of Radiology, Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
    Eur J Nucl Med Mol Imaging 34:2150. 2007
  4. pmc Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels
    Erik S Mittra
    Molecular Imaging Program, Department of Radiology, Division of Nuclear Medicine, Stanford Hospital and Clinics, 300 Pasteur Dr, Room H2200, Stanford, CA 94305 5281, USA
    Radiology 260:182-91. 2011
  5. doi request reprint Positron emission tomography/computed tomography: the current technology and applications
    Erik Mittra
    Division of Nuclear Medicine, Stanford Hospital and Clinics, 300 Pasteur Drive, Room H0101, Stanford, CA 94305, USA
    Radiol Clin North Am 47:147-60. 2009
  6. doi request reprint Prospective comparison of combined 18F-FDG and 18F-NaF PET/CT vs. 18F-FDG PET/CT imaging for detection of malignancy
    Frank I Lin
    Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Dr, Room H 2230, Stanford, CA 94305, USA
    Eur J Nucl Med Mol Imaging 39:262-70. 2012
  7. pmc 18F-FDG PET/CT evaluation of patients with ovarian carcinoma
    Andrei H Iagaru
    Department of Radiolog, Stanford Hospital and Clinics, Stanford, CA, USA
    Nucl Med Commun 29:1046-51. 2008
  8. doi request reprint Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, Stanford, California, USA
    J Nucl Med 50:501-5. 2009
  9. doi request reprint FDG-PET/CT in cancers of the head and neck: what is the definition of whole body scanning?
    Andrei Iagaru
    Stanford Hospital and Clinics, Division of Nuclear Medicine, 300 Pasteur Dr, Room H 0101, Stanford, CA 94305, USA
    Mol Imaging Biol 13:362-7. 2011
  10. ncbi request reprint Preclinical efficacy of the anti-hepatocyte growth factor antibody ficlatuzumab in a mouse brain orthotopic glioma model evaluated by bioluminescence, PET, and MRI
    Erik S Mittra
    Authors Affiliations Molecular Imaging Program, Department of Radiology, System Medicine, Department of Pediatrics, Division of Neuropathology, Department of Pathology, Merck Research Laboratories, Palo Alto, California AVEO Pharmaceuticals Inc, Cambridge, Massachusettes and Bio X Program, Department of Bioengineering, Department of Materials Science and Engineering, Stanford University, Stanford
    Clin Cancer Res 19:5711-21. 2013

Detail Information

Publications14

  1. ncbi request reprint Comparative morphometrics of the primate apical tuft
    Erik S Mittra
    Division of Nuclear Medicine, Stanford University, Stanford, CA 94305, USA
    Am J Phys Anthropol 134:449-59. 2007
    ..The implications of these findings for hypotheses about the association of apical tuft size and tool making in the hominin fossil record are discussed...
  2. ncbi request reprint A case of three synchronous primary tumors demonstrated by F-18 FDG PET
    Erik Mittra
    Nuclear Medicine Service, VA Palo Alto Health Care System, Palo Alto, California, USA
    Clin Nucl Med 32:666-7. 2007
    ..A staging PET scan additionally showed increased left tonsillar uptake. Subsequent biopsy confirmed squamous cell carcinoma of the left tonsil. The demonstration of 3 synchronous primaries by PET is probably rare...
  3. ncbi request reprint Concurrent metabolic and osseous metastatic disease on a Tc99m-MDP bone scan
    Erik Mittra
    Department of Radiology, Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
    Eur J Nucl Med Mol Imaging 34:2150. 2007
  4. pmc Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels
    Erik S Mittra
    Molecular Imaging Program, Department of Radiology, Division of Nuclear Medicine, Stanford Hospital and Clinics, 300 Pasteur Dr, Room H2200, Stanford, CA 94305 5281, USA
    Radiology 260:182-91. 2011
    ....
  5. doi request reprint Positron emission tomography/computed tomography: the current technology and applications
    Erik Mittra
    Division of Nuclear Medicine, Stanford Hospital and Clinics, 300 Pasteur Drive, Room H0101, Stanford, CA 94305, USA
    Radiol Clin North Am 47:147-60. 2009
    ..Additionally, novel radiopharmeuticals are under development, many of which are target cellular processes that are more specific than glucose metabolism...
  6. doi request reprint Prospective comparison of combined 18F-FDG and 18F-NaF PET/CT vs. 18F-FDG PET/CT imaging for detection of malignancy
    Frank I Lin
    Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Dr, Room H 2230, Stanford, CA 94305, USA
    Eur J Nucl Med Mol Imaging 39:262-70. 2012
    ..In the current study, we compared the clinical usefulness of a combined (18)F-FDG/(18)F-NaF PET/CT scan with that of a separate (18)F-FDG-only PET/CT scan...
  7. pmc 18F-FDG PET/CT evaluation of patients with ovarian carcinoma
    Andrei H Iagaru
    Department of Radiolog, Stanford Hospital and Clinics, Stanford, CA, USA
    Nucl Med Commun 29:1046-51. 2008
    ..Therefore, we were prompted to review our experience with PET/CT in the management of patients with ovarian carcinoma...
  8. doi request reprint Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, Stanford, California, USA
    J Nucl Med 50:501-5. 2009
    ..Sodium (18)F was previously used for bone imaging and can be used as a PET/CT skeletal tracer. The combined administration of (18)F and (18)F-FDG in a single PET/CT study for cancer detection has not been reported to date...
  9. doi request reprint FDG-PET/CT in cancers of the head and neck: what is the definition of whole body scanning?
    Andrei Iagaru
    Stanford Hospital and Clinics, Division of Nuclear Medicine, 300 Pasteur Dr, Room H 0101, Stanford, CA 94305, USA
    Mol Imaging Biol 13:362-7. 2011
    ..e., eyes to thighs) may yield little additional information. Therefore, we were prompted to review our experience with PET/computed tomography (CT) in the management of patients with HNSCC and NPC...
  10. ncbi request reprint Preclinical efficacy of the anti-hepatocyte growth factor antibody ficlatuzumab in a mouse brain orthotopic glioma model evaluated by bioluminescence, PET, and MRI
    Erik S Mittra
    Authors Affiliations Molecular Imaging Program, Department of Radiology, System Medicine, Department of Pediatrics, Division of Neuropathology, Department of Pathology, Merck Research Laboratories, Palo Alto, California AVEO Pharmaceuticals Inc, Cambridge, Massachusettes and Bio X Program, Department of Bioengineering, Department of Materials Science and Engineering, Stanford University, Stanford
    Clin Cancer Res 19:5711-21. 2013
    ..Ficlatuzumab is a novel therapeutic agent targeting the hepatocyte growth factor (HGF)/c-MET pathway. We summarize extensive preclinical work using this agent in a mouse brain orthotopic model of glioblastoma...
  11. doi request reprint Prognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin-99mTc-sulfur colloid SPECT
    Marnix G E H Lam
    Division of Interventional Radiology, Stanford University School of Medicine, Stanford, California
    J Nucl Med 54:2055-61. 2013
    ..Planning hepatic (90)Y radioembolization activity requires balancing toxicity with efficacy. We developed a dual-tracer SPECT fusion imaging protocol that merges data on radioactivity distribution with physiologic liver mapping...
  12. doi request reprint 131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin lymphoma
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
    Mol Imaging Biol 12:198-203. 2010
    ..Both target CD20 receptors present on the surface of lymphocytes. We present our clinical experience with Bexxar and Zevalin in the management of low-grade refractory or relapsed NHL...
  13. ncbi request reprint Recurrent silent thyroiditis: a report of four patients and review of the literature
    Erik S Mittra
    Division of Nuclear Medicine, Stanford University Medical Center and Clinics, Stanford, California 94305, USA
    Thyroid 17:671-5. 2007
    ..Three were treated with radioablative iodine therapy during the recovery phase of an episode; they became hypothyroid and take replacement l-thyroxine. They have remained symptom free...
  14. ncbi request reprint Evaluation of trabecular mechanical and microstructural properties in human calcaneal bone of advanced age using mechanical testing, microCT, and DXA
    Erik Mittra
    Department of Radiology Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Dr, Rm H0101, Stanford, CA 94305, USA
    J Biomech 41:368-75. 2008
    ..Ultimate stress, however, is better correlated with trabecular number than thickness. As such, primary prevention of osteoporosis may be more important than later countermeasures for bone loss...